Dr. John Cush RheumNow
4 years 7 months ago
TB is uncommon in idiopathic inflamm myopathies (3.58%), esp in endemic areas (eg, Asia). Disseminated and Extra-pulmonary (47%) was as common as pulmonary TB (49%); TB Muscle dz seen in 24%. More with M. TB than Non-tuberculous Mycobacteria https://t.co/h6uDsdWj3f
Dr. John Cush RheumNow
4 years 7 months ago
Retrospective study of 84 pts with Erosive Hand OsteoArthritis (EHOA)- 89% females DIPs erosions scores were higher than PIP’s. Comorbid dz = crystal arthritis (8%), RA (5%) & PsA (1%), Pain usually >5/10 w/ 1/3 responding to NSAIDs. Big Unmet need! https://t.co/jQ3yNgaZBA
Dr. John Cush RheumNow
4 years 7 months ago
Treatment of Complex regional pain syndrome type-I (CRPS-I) in adults is difficult! A Systematic review shows that only parenteral bisphosphonates (and maybe ketamine) lowered VAS/NRS pain scales vs placebo. https://t.co/m4SpO4P96J
The July 2021 RheumNow “Live Vote” surveyed US and non-US rheumatologists on their knowledge and practices when dealing with the bone disorder, X-linked hypophosphatemia (XLH). Although rare, XLH can be a diagnostic consideration in patients with recurrent fractures, rickets, osteomalacia and a family history of fractures.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout.
Dr. John Cush RheumNow
4 years 7 months ago
Persons living with diagnosed HIV (PLWDH) have more hospitalizations and death from COVID-19 than those not HIV+. In 100K PLWDH, 63%) were fully vaccinated, 4% partly Vax & 32% no Vax. VAX in PLWDH was lower than gen population (63% vs 75%) https://t.co/oegf5WjmNF
Two recent analyses from the USA and Canada point to a significant unmet need with regard to pediatric rheumatologists.
The 2015 pediatric rheumatology workforce in the US was evaluated by the American College of Rheumatology, estimating the Pediatric rheumatology supply and demand projected through 2030.
Dr. John Cush RheumNow
4 years 7 months ago
In the USA, the prevalence of Vitiligo in adults is between 0.76% (1.9 million cases in 2020) and 1.11% (2.8 million cases in 2020). Approximately 40% of adult vitiligo in the US may be undiagnosed. https://t.co/rsyoIbHmS8
Dr. John Cush RheumNow
4 years 7 months ago
Radiographic progression in AxSpA studied in 101 Spanish Pts - pts w/ sustained low ASDAS had less XRay progression than those with active Dz (2.33 vs 1.76, p=0.027). Long term TNFi use didnt influence progression until the 3rd Yr https://t.co/KHCdzbqhzr
Dr. John Cush RheumNow
4 years 7 months ago
FDA has expanded its approval of REMDESIVIR for use in non-hospitalizedadults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease. Previously, Veklury was limited to hospitalized COVID-19 pts. https://t.co/dHbomchfB5
The 2022 ACR/EULAR revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA) have been revised and validated for use in clinical research.
This international cohort of vasculitis and comparator cases were to develop and validate criteria based on 91 candidate variables. By regression analysis these were narrowed to 11 items for the diagnosis of EPGA; 7 of which were retained.
The ACR/EULAR 2022 revised classification criteria for granulomatosis with polyangiitis (GPA) have been updated with performance characteristics and are validated for use in clinical research.
The 2022 ACR/EULAR classification criteria for microscopic polyangiitis (MPA) have been developed, validated and are now ready for use in clinical research.
An international cohort of patients with vasculitis or comparator diseases were recruited to first develop criteria and then validate criteria.
Dr. John Cush RheumNow
4 years 7 months ago
Interested in our most popular articles? Head over to RheumNow.
https://t.co/8JLpph3or8
